Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why DexCom (DXCM) Might Surprise This Earnings Season

Kirkland Lake Gold

NextEra Energy

Block

Forget running and hiding: A recession is the perfect time to buy into these dominant companies.

4 Must-Own Recession Stocks

BOSTON--(BUSINESS WIRE)--Current Health today announced it has partnered with Dexcom to add continuous glucose monitoring (CGM) capabilities to Current Health’s AI-powered remote patient monitoring (RPM) platform. By continuously monitoring patients’ glucose levels – largely considered the fifth vital sign – the Current Health platform will empower health systems to secure actionable and comprehensive insights into overall patient health, resulting in improved patient outcomes and decreased hea

Current Health Partners with Dexcom to Offer Healthcare Providers Continuous, Remote Glucose Monitoring of Patients

The company is having a good year on the stock market, but how long can that last?

Is Dexcom Stock a Buy?

Zoom Video

Datadog

DocuSign

After a long winning streak, the Nasdaq finally gave up ground.

Nasdaq Sinks 227 Points as Zoom, Other Investor Favorites Reverse and Fall Hard

PayPal

Regeneron Pharmaceuticals

Find out who's winning out among hundreds of companies.

The 3 Best S&P 500 Stocks So Far in 2020

Seagen

Teladoc

Vertex Pharmaceuticals

West Pharmaceutical Services

Teladoc Health, Dexcom, Vertex Pharmaceuticals, Seattle Genetics and West Pharmaceutical Services are medical stocks in or near buy zones.
The post Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy Zones appeared first on Investor's Business Daily.

Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy Zones

In the latest trading session, DexCom (DXCM) closed at $405.40, marking a +1.81% move from the previous day.

DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know

AmerisourceBergen

NRG Energy

These are the stocks with the best value, fastest growth, and most momentum for July.

Top Stocks for July 2020

Biogen

These are the health care stocks with the best value, fastest growth, and most momentum for July.

Top Health Care Stocks for July 2020

JD.com

Repligen

While many companies were unable to avoid the wrath of the coronavirus pandemic, these three companies stood out as big winners.

3 Great Growth Stocks That Kept Climbing in This Tough Market

Tandem Diabetes Care

Which of these two diabetes partners is more likely to be the bigger winner over the long run?

Better Buy: DexCom vs. Tandem Diabetes Care

Livongo Health Inc

Insulet

As the prevalence of diabetes has grown, these companies are looking for solutions.

3 Diabetes Monitoring Companies That Are Recession-Proof

iRhythm Technologies

The coronavirus pandemic is changing how people access health care, and is helping give rise to the nascent industry owned by telemedicine and remote-monitoring companies.
The post How The Pandemic Is Stoking A Multibillion-Dollar Shift In Health Care appeared first on Investor's Business Daily.

How The Pandemic Is Stoking A Multibillion-Dollar Shift In Health Care

Fortinet

Tractor Supply

Tesla

Here're five big stock winners from the first 100 days of the coronavirus pandemic that ravaged the global economy and shook the stock market.

5 Best Stocks From 100 Days of Coronavirus

Abbott Labs

ResMed

Let's keep a watch on three stocks that have displayed strong performance amid market turmoil led by the ongoing pandemic.

3 MedTech Stocks to Watch Amid Coronavirus Catastrophe

Henkel AG & Co KGaA

Moderna

Netflix

Peloton

Reckitt Benckiser Group PLC

Tencent Holdings Limited

Here we discuss four sectors for which COVID-19 has opened up enormous growth prospects.

Economic Recovery Debate Heats Up: 4 Sectors Holding Ground

Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments

3 Diabetes Management Stocks in the Spotlight Amid Coronavirus

ABIOMED

NVIDIA

The Nasdaq Composite Index closed on Wednesday above 10,000 for the first time in history as investors continue their optimistic bet on the economy recovering from the coronavirus-related shutdown.

Top-Performing Nasdaq Stocks So Far in 2020

DexCom (DXCM) announces the receipt of CE Marking across Europe for its G6 CGM System.

DexCom's (DXCM) G6 CGM System Gets CE Marking in Europe

DexCom stock just pulled back to a historically bullish trendline on the charts

DXCM Could Bounce Back Says Signal

Amazon

Palo Alto Networks

These high-growth industries are where you should consider putting your money to work.

4 Industries That'll Thrive in the New Bull Market

Carrier Global

MarketAxess Holdings

Newmont Mining

NortonLifeLock

ServiceNow

In a year dominated by COVID-19 news, many of the top-performing companies were boosted by the pandemic, but the top performer benefited from longer-term trends.

Top Performers in the S&P 500 This Year

Axon Enterprise

Beyond Meat

Century Aluminum

Chewy

Orion Group Hlds

PotlatchDeltic

Sarepta Therapeutics

TeleNav

Twilio

These sectors came up with stellar earnings beat in the recent cycle. Investors can play the associated stocks that delivered an earnings surprise.

Do You Always Look for Earnings Beat? 5 Sectors to Play

News for DexCom Stock (DXCM)